OmniAb to Participate in Two Investor Conferences in September
-
H.C. Wainwright 26th AnnualGlobal Investment Conference ,September 9-11 at theLotte New York Palace Hotel . Management will deliver a corporate presentation onTuesday, September 10 th at2:30 p.m. Eastern Time and will hold one-on-one meetings with investors.
-
Craig-Hallum Bioprocessing Virtual Conference ,September 19 th. Management will participate in a fireside chat and will hold one-on-one and small group meetings with investors.
About
We believe the
Our proprietary transgenic animals, including OmniRat®, OmniChicken® and OmniMouse® have been genetically modified to generate antibodies with human sequences to streamline the development of human therapeutic candidates. OmniFlic® and OmniClic® are fixed or common light-chain rats and chickens, respectively, designed to facilitate the discovery of bispecific antibodies. OmniTaur™ provides cow-inspired antibodies with unique structural characteristics for challenging targets. OmnidAb™, is an in vivo platform for the discovery of single domain antibodies based upon a human VH scaffold that affinity matures in a chicken host environment to provide a functionally diverse immune repertoire unavailable from mammalian systems. Our proprietary technologies are joined with and leverage OmniDeep™, which is a suite of in silico, AI and machine learning tools for therapeutic discovery and optimization that are woven throughout our various technologies and capabilities. Additionally, an established core competency focused on ion channels and transporters further differentiates OmniAb’s technology and creates opportunities in many important and emerging target classes.
For more information, please visit www.omniab.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240826074755/en/
investors@OmniAb.com
X (Twitter) @OmniAbTech
(510) 768-7760
Source: